Muscle Selection for Botulinum Toxin A Injection in Poststroke Elbow Flexor Spasticity

Sponsor
Izmir Katip Celebi University (Other)
Overall Status
Completed
CT.gov ID
NCT04036981
Collaborator
(none)
55
1
24.7
2.2

Study Details

Study Description

Brief Summary

Botulinum toxin A (BoNT A) has been reported to be effective in the treatment of elbow flexor spasticity. Although BoNT A is an efficacious treatment option, there is a debate in the selection of target muscle(s) for BoNT injection in the treatment of poststroke elbow flexor spasticity. The decision of muscle selection for BoNT A injection is mostly made according to the physical examination findings in real life practice.One of the guiding findings in this decision is the position of the spastic arm.

In this study, hypothesis is that the change in severity of spasticity with BoNT A injection differs depending on the muscle selection in chronic stroke patients with elbow flexor and forearm pronator spasticity.

Condition or Disease Intervention/Treatment Phase
  • Drug: Botulinum toxin type A

Detailed Description

Botulinum neurotoxin A (BoNT A) has been reported to be effective in the treatment of elbow flexor spasticity. In the treatment of poststroke elbow flexor spasticity with BoNT A, three main muscles injected individually or in combination are musculus biceps brachii, musculus brachialis and musculus brachioradialis. Although BoNT is an efficacious treatment option, there is a debate in the selection of target muscle(s) for BoNT A injection in the treatment of poststroke elbow flexor spasticity. Superficiality of the biceps brachii muscle makes it an easy target for botulinum toxin injection. In dynamic electromyography studies, it has been reported that brachioradialis muscle is the most common contributor one to elbow flexion spasticity, followed by biceps brachii muscle. In the diagnostic selective nerve blocks, the brachialis muscle has been reported to be foreground. In a recent study using the modified Delphi Method Design, the expert committee was only fully agree on the application of BoNT A into the brachioradialis muscle.

The decision of muscle selection for BoNT A injection is mostly made according to the physical examination findings in real life practice. One of the guiding findings in this decision is the position of the spastic arm. The typical pattern of spastic elbow and forearm in patients with stroke is characterized by flexion at the elbow, and pronation in the forearm. As far as the investigators know, there has not been carried out any study investigating the effect of muscle selection for BoNT application on the treatment outcome (severity of spasticity) in chronic stroke patients with elbow flexor and forearm pronator spasticity.

The aim of this study is to investigate whether treatment response (change in severity of spasticity) differs according to BoNT A injected muscle in chronic stroke patients with elbow flexor and forearm pronator spasticity.

Study Design

Study Type:
Observational
Actual Enrollment :
55 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
The Effect of Muscle Selection for Botulinum Toxin A Injection on the Treatment Outcome in Poststroke Elbow Flexor Spasticity
Actual Study Start Date :
May 10, 2019
Actual Primary Completion Date :
May 3, 2021
Actual Study Completion Date :
Jun 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Brachialis

Targeted muscle for BoNT A injection

Drug: Botulinum toxin type A
Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
Other Names:
  • Botox
  • Dysport
  • Biceps

    Targeted muscle for BoNT A injection

    Drug: Botulinum toxin type A
    Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
    Other Names:
  • Botox
  • Dysport
  • Brachialis plus Brachioradialis

    Targeted muscles for BoNT A injection

    Drug: Botulinum toxin type A
    Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
    Other Names:
  • Botox
  • Dysport
  • Outcome Measures

    Primary Outcome Measures

    1. Dynamic Component of Spasticity (Spasticity Angle) [up to 4 week]

      According to the Modified Tardieu Scale, the difference between the angle of slow passive motion and the angle of muscle reaction represents the dynamic component of spasticity (spasticity angle) in degree. A big difference suggests spasticity while the low difference suggests muscular contracture. In this study, dynamic component of spasticity (spasticity angle) of elbow joint at forearm pronation position will be evaluated.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Chronic (equal to or upper than 1 year) stroke patients with position of elbow flexion and forearm pronation while standing or sitting

    • Grade 2 or 3 elbow flexor spasticity and grade 1 to 3 forearm pronator spasticity according to Modified Ashworth Scale

    • Stage 2 or 3 Brunnstrom's motor recovery stage of upper extremity

    • To agree to participate in the study

    Exclusion Criteria:
    • <18 years old

    • Pregnancy

    • Botulinum toxin injection within the last three months

    • Presence of elbow contracture

    • History of operation to spastic upper extremity

    • Spasticity due to other causes other than stroke

    • Do not agree to participate in the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 İlker Şengül İzmir In The USA Or Canada, Please Select... Turkey 35360

    Sponsors and Collaborators

    • Izmir Katip Celebi University

    Investigators

    • Principal Investigator: İlker Şengül, M.D., Izmir Katip Celebi University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    ilker şengül, Principal Investigator, Izmir Katip Celebi University
    ClinicalTrials.gov Identifier:
    NCT04036981
    Other Study ID Numbers:
    • 2018-KAE-0230
    First Posted:
    Jul 30, 2019
    Last Update Posted:
    Jun 23, 2021
    Last Verified:
    Jun 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by ilker şengül, Principal Investigator, Izmir Katip Celebi University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 23, 2021